Development of live attenuated influenza vaccines against pandemic influenza strains
- PMID: 24867587
- DOI: 10.1586/14760584.2014.922417
Development of live attenuated influenza vaccines against pandemic influenza strains
Abstract
Avian and animal influenza viruses can sporadically transmit to humans, causing outbreaks of varying severity. In some cases, further human-to-human virus transmission does not occur, and the outbreak in humans is limited. In other cases, sustained human-to-human transmission occurs, resulting in worldwide influenza pandemics. Preparation for future pandemics is an important global public health goal. A key objective of preparedness is to gain an understanding of how to design, test, and manufacture effective vaccines that could be stockpiled for use in a pandemic. This review summarizes results of an ongoing collaboration to produce, characterize, and clinically test a library of live attenuated influenza vaccine strains (based on Ann Arbor attenuated Type A strain) containing protective antigens from influenza viruses considered to be of high pandemic potential.
Keywords: LAIV; intranasal influenza vaccine; pandemic influenza vaccine.
Similar articles
-
Seed viruses containing novel avian HA and NA antigens for prevention against potential influenza pandemic.Dev Biol (Basel). 2002;110:135-41. Dev Biol (Basel). 2002. PMID: 12477316
-
Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.Expert Rev Vaccines. 2015 Mar;14(3):395-412. doi: 10.1586/14760584.2015.979159. Epub 2015 Jan 2. Expert Rev Vaccines. 2015. PMID: 25555687 Review.
-
Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories.Vaccine. 2016 Oct 26;34(45):5436-5441. doi: 10.1016/j.vaccine.2016.08.018. Epub 2016 Sep 1. Vaccine. 2016. PMID: 27593158 Free PMC article.
-
Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.Wkly Epidemiol Rec. 2012 Oct 19;87(42):401-12. Wkly Epidemiol Rec. 2012. PMID: 23113329 English, French. No abstract available.
-
Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.Expert Rev Vaccines. 2015;14(10):1313-29. doi: 10.1586/14760584.2015.1075883. Epub 2015 Aug 6. Expert Rev Vaccines. 2015. PMID: 26289975 Review.
Cited by
-
Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins.Viruses. 2021 Apr 6;13(4):625. doi: 10.3390/v13040625. Viruses. 2021. PMID: 33917411 Free PMC article. Review.
-
A replication-deficient H9N2 influenza virus carrying H5 hemagglutinin conferred protection against H9N2 and H5N1 influenza viruses in mice.Front Microbiol. 2022 Nov 15;13:1042916. doi: 10.3389/fmicb.2022.1042916. eCollection 2022. Front Microbiol. 2022. PMID: 36458187 Free PMC article.
-
A live attenuated vaccine prevents replication and transmission of H7N9 virus in mammals.Sci Rep. 2015 Jun 10;5:11233. doi: 10.1038/srep11233. Sci Rep. 2015. PMID: 26058711 Free PMC article.
-
Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.mBio. 2019 Sep 17;10(5):e02180-19. doi: 10.1128/mBio.02180-19. mBio. 2019. PMID: 31530680 Free PMC article.
-
The expression of B & T cell activation markers in children's tonsils following live attenuated influenza vaccine.Hum Vaccin Immunother. 2015;11(7):1663-72. doi: 10.1080/21645515.2015.1032486. Hum Vaccin Immunother. 2015. PMID: 26148331 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical